Olopatadină Rompharm (Olopatadine)

Olopatadine, the active ingredient in Olopatadină Rompharm, is an antihistamine presented as a 0.1% ophthalmic solution for topical ocular use. It treats allergic eye inflammation and related symptoms in patients with seasonal or perennial allergies. GNH USA supplies Olopatadină Rompharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olopatadine is an antihistamine that acts on ocular allergic pathways to relieve inflammation and itching. - Allergic conjunctivitis: reduces eye redness, itching and tearing caused by allergens. - Vernal keratoconjunctivitis: helps control chronic inflammation in seasonal eye allergy. - Seasonal allergic rhinitis (when supplied as oral form): alleviates nasal itching and sneezing associated with pollen exposure.

Olopatadine is generally well tolerated, but ocular and systemic reactions can occur.

Common Side Effects: - Burning or stinging sensation in the eye. - Transient blurred vision. - Mild headache. - Dry eye sensation. - Unpleasant taste after administration. - Redness of the eyelid margin.

Serious or Rare Side Effects: - Corneal edema or ulceration. - Severe allergic reaction (anaphylaxis). - Increased intra‑ocular pressure. - Persistent eye irritation or infection. - Vision loss. - Systemic hypersensitivity (rash, swelling).

Before using Olopatadină Rompharm, consider the following safety measures. - Pregnancy: consult a healthcare professional before use. - Breastfeeding: use only if the benefit outweighs potential risk. - Contact lens wearers: remove lenses prior to instillation and wait at least 15 minutes before reinserting. - Known hypersensitivity: avoid if allergic to olopatadine or any excipient. - Glaucoma patients: monitor intra‑ocular pressure regularly. - Store at room temperature: keep in the original container, protect from light and moisture.

Olopatadine may interact with other medications; review the following categories.

Major Interactions (Avoid): - Concomitant use of other topical antihistamines: may increase local irritation. - Systemic MAO inhibitors: theoretical risk of additive antihistaminic effects. - CYP3A4 inhibitors (e.g., ketoconazole): could raise systemic exposure in oral formulations.

Moderate Interactions (Monitor Closely):\n- Anticholinergic eye drops: may exacerbate dry‑eye symptoms. - Topical ophthalmic NSAIDs: potential for increased ocular irritation. - Systemic sedating antihistamines: may enhance drowsiness if oral olopatadine is used.